FY2025 EPS Estimates for Disc Medicine Reduced by Analyst

Disc Medicine, Inc. (NASDAQ:IRON - Free Report) - Cantor Fitzgerald lowered their FY2025 EPS estimates for Disc Medicine in a report issued on Thursday, May 8th. Cantor Fitzgerald analyst K. Kluska now expects that the company will post earnings of ($4.69) per share for the year, down from their previous forecast of ($4.59). Cantor Fitzgerald currently has a "Overweight" rating and a $132.00 price target on the stock. The consensus estimate for Disc Medicine's current full-year earnings is ($4.07) per share.

Disc Medicine (NASDAQ:IRON - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported ($1.02) earnings per share for the quarter, missing analysts' consensus estimates of ($0.99) by ($0.03).

A number of other equities analysts also recently commented on the company. HC Wainwright restated a "buy" rating and set a $118.00 target price on shares of Disc Medicine in a report on Tuesday, January 21st. Morgan Stanley restated an "overweight" rating and issued a $85.00 price objective on shares of Disc Medicine in a report on Friday, March 7th. TD Cowen assumed coverage on shares of Disc Medicine in a research report on Thursday, February 27th. They issued a "buy" rating for the company. BMO Capital Markets boosted their price target on shares of Disc Medicine from $112.00 to $120.00 and gave the company an "outperform" rating in a research report on Monday. Finally, Scotiabank increased their price target on shares of Disc Medicine from $73.00 to $75.00 and gave the stock a "sector outperform" rating in a research note on Monday, March 3rd. Ten equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $98.80.

Disc Medicine Trading Down 1.3%

NASDAQ IRON traded down $0.62 on Monday, hitting $45.73. The company's stock had a trading volume of 218,935 shares, compared to its average volume of 349,741. The firm has a market cap of $1.58 billion, a P/E ratio of -11.49 and a beta of 0.77. Disc Medicine has a 52-week low of $30.65 and a 52-week high of $68.73. The company's 50-day simple moving average is $46.54 and its 200 day simple moving average is $54.93.

Insider Transactions at Disc Medicine

In other news, Director Mona Ashiya sold 202,146 shares of Disc Medicine stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $54.29, for a total value of $10,974,506.34. Following the completion of the transaction, the director now owns 208,742 shares of the company's stock, valued at $11,332,603.18. The trade was a 49.20% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider William Jacob Savage sold 2,100 shares of the stock in a transaction dated Friday, May 2nd. The shares were sold at an average price of $50.17, for a total transaction of $105,357.00. Following the sale, the insider now directly owns 66,398 shares in the company, valued at $3,331,187.66. This trade represents a 3.07% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 356,290 shares of company stock valued at $19,336,901 in the last three months. 4.24% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Corebridge Financial Inc. increased its position in shares of Disc Medicine by 14.0% during the first quarter. Corebridge Financial Inc. now owns 11,180 shares of the company's stock valued at $555,000 after acquiring an additional 1,371 shares in the last quarter. MetLife Investment Management LLC boosted its stake in Disc Medicine by 10.9% during the 1st quarter. MetLife Investment Management LLC now owns 13,454 shares of the company's stock valued at $668,000 after purchasing an additional 1,322 shares during the last quarter. Quantbot Technologies LP increased its holdings in shares of Disc Medicine by 189,025.0% in the 1st quarter. Quantbot Technologies LP now owns 7,565 shares of the company's stock worth $376,000 after purchasing an additional 7,561 shares in the last quarter. Wellington Management Group LLP raised its stake in shares of Disc Medicine by 67.9% in the first quarter. Wellington Management Group LLP now owns 2,343,499 shares of the company's stock worth $116,331,000 after purchasing an additional 948,094 shares during the last quarter. Finally, Northern Trust Corp raised its stake in shares of Disc Medicine by 11.7% in the first quarter. Northern Trust Corp now owns 208,813 shares of the company's stock worth $10,365,000 after purchasing an additional 21,796 shares during the last quarter. Institutional investors own 83.70% of the company's stock.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.